Actinium Pharmaceuticals, Inc (ATNM) is a publicly traded Healthcare sector company. As of May 21, 2026, ATNM trades at $1.20 with a market cap of $36.71M and a P/E ratio of -1.55. ATNM moved +1.30% today. Year to date, ATNM is -19.31%; over the trailing twelve months it is -36.07%. Its 52-week range spans $0.95 to $2.41. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces ATNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own ATNM include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Actinium Pharmaceuticals, Inc.
| Metric | Value |
|---|---|
| Price | $1.20 |
| Market Cap | $36.71M |
| P/E Ratio | -1.55 |
| EPS | $-0.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.41 |
| 52-Week Low | $0.95 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $90.00K |
| Net Income | $-23.47M |
| Gross Margin | 0.00% |
3 analysts cover ATNM: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.